A company located here in the United States that specializes in marijuana formulation-based drug development, Cannabis Science Inc., has announced the submission of a patent application in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders."
The theme of said patent is the development of cannabinoid-based formulations with the intention of treating an assortment of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety and sleep disorders.
According to the World Health Organization (WHO), approximately 450 million people suffer from some form of mental or neurobehavioral disorder or brain condition on a worldwide basis, with one in four people meeting criteria for such a condition or disorder at some point throughout the span of their lifetime.
Some of the targeted neurobehavioral conditions that have a universal impact include sleeping and sleep-related disorders. The annual direct cost of sleep-related problems in the United States is nearly 16 billion dollars, with an additional 50 to 100 billion dollars in indirect costs.
"Being personally and professionally close to people with ADHD, anxiety, and sleeping disorders, I am excited about the Board's decision to focus on treating these ailments in the Company's overall strategy," Cannabis Science Inc.'s COO and general counsel Chad Johnson avowed.
Companies such as Cannabis Science Inc. are on the forefront of scientific research regarding the plethora of medicinal uses that the marijuana plant has to offer all mankind, but will pharmacological-type marijuana-based drugs only ensure that the whole plant remains illegal in some states? It seems that if these types of companies continue to prove that they can extract certain cannabinoids in order to formulate their medications that it would only strengthen the arguments of those that oppose legalizing the whole plant for medical purposes. Let us know what you think in the comment section below.